Company news

ImmueOco: The Invention patent for IMM0306 was authorized by Japan Patent Office

Date:2022-03-10 Views:500

    On March 9, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") declared that IMM0306, a bispecific fusion protein targeting CD47 and CD20 was authorized by the Japan Patent Office (Japanese Patent Application No.: JP2019 - 542396). Granted a patent in a major global pharmaceutical market such as Japan, IMM0306 will greatly improve the market competitiveness of the company.

    IMM0306 has been authorized by the China Intellectual Property Office for invention patents (China Patent Application No.: CN201710151979.6)and also been authorized by National Medical Products Administration (NMPA) in China and the U.S. Food and Drug Administration (FDA) for clinical trials on December 28, 2020 and January 9, 2021 respectively.

    Founder, Chairman and CEO of the Company, Dr. Tian Wenzhi said: "We are very pleased to know that our IMM0306 invention patent has been authorized by the Japan Patent Office. IMM0306 is an antibody-receptor recombinant protein (mAb-Trap) that targets both CD47 and CD20, and is the first CD47xCD20 bispecific molecule to enter clinical trials globally. IMM0306 does not bind to human red blood cells, the efficacy of the same dose is significantly better than that of Rituximab and it is hopeful that it will surpass Rituximab in the future as alternative first line treatment choice for patients with B-cell lymphoma. At present, the clinical phase I trial research conducted in China progresses rapidly, and the preliminary safety and efficacy data is encouraging. Clinical trials in the United States have also started, and we feel confident to the future of IMM0306.”

    "We will continue to further expand clinical trial research of imm0306 to speed up the launch of IMM0306 to the market so as to benefit cancer patients."

About IMM0306

    IMM0306 is an antibody receptor recombinant protein (mAb-Trap) targeting CD47 and CD20 at the same time. It is the first in class in the world. It is a bispecific antibody drug candidate with independent intellectual property rights of ImmuneOnco. It can act on tumor targets and regulate immune system at the same time, and exert strong anti-tumor effect by activating macrophages and NK cells.